MARKET

NERV

NERV

Minerva
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.060
-0.090
-2.86%
Pre Market: 3.042 -0.018 -0.59% 08:11 03/04 EST
OPEN
3.180
PREV CLOSE
3.150
HIGH
3.180
LOW
3.020
VOLUME
2.11K
TURNOVER
--
52 WEEK HIGH
15.22
52 WEEK LOW
1.810
MARKET CAP
130.58M
P/E (TTM)
-5.6983
1D
5D
1M
3M
1Y
5Y
Minerva Neurosciences to Report Fiscal 2020 Fourth Quarter and Year End Financial Results and Business Updates on March 8, 2021
Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results and business updates for ...
GlobeNewswire · 2d ago
Global Receptor Tyrosine Protein Kinase Targeted Drugs Market Analysis by Manufacturers, Regions, Type and Application to 2027
Feb 22, 2021 (The Expresswire) -- Global “Receptor Tyrosine Protein Kinase Targeted Drugs Market” forecast 2027; research report analyzed the existing state...
The Express Wire · 02/22 09:27
Receptor Tyrosine Protein Kinase ERBB 4 Market By Industry Research, Supply, Size, Share and Prospects 2020-2027 By Ameco Research
pune, India, Mon, 22 Feb 2021 02:44:50 / Comserve Inc. / -- Receptor Tyrosine Protein Kinase ERBB 4 market is segmented by Type, and by Application. Players,...
Comserve · 02/22 07:47
Receptor Tyrosine Protein Kinase ERBB 4 Market 2021 Industry Supply, Growth, Demand, Size, Applications and Manufacturers Analysis Research Report 2027, Says Industry Research Biz
Feb 18, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." The global “Receptor Tyrosine Protein...
The Express Wire · 02/18 05:07
Schizophrenia Pipeline: Analysis of 90+ key pipeline therapies, 90+ key pharma competitors, unmet needs, and opportunities
Los Angeles, USA, Feb 16, 2021 (GLOBE NEWSWIRE via COMTEX) -- Los Angeles, USA, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Schizophrenia Pipeline: Analysis of 90+ key...
GlobeNewswire · 02/17 01:15
Receptor Tyrosine Protein Kinase Targeted Drugs Market Size Segmentation: Research, Analysis, Trends, Market Share, Competitors, Regions, Applications and Forecasts Up to 2026
Feb 10, 2021 (The Expresswire) -- “Receptor Tyrosine Protein Kinase Targeted Drugs Market" forecast report provides a detailed evaluation of the market by...
The Express Wire · 02/10 11:09
Insomnia Medication Market Global Development, Industry Trends, Demand and Growth Analysis and Forecasts 2020 to 2027 By Ameco Research
pune, India, Tue, 09 Feb 2021 06:52:36 / Comserve Inc. / -- Insomnia Medication market size by analysing historical data and future prospect. Regionally,...
Comserve · 02/09 11:54
Receptor Tyrosine Protein Kinase Targeted Drugs Market to Deliver Prominent Growth & Striking Opportunities, Analysis, Demand, Growth by Top Key Players, Global Forecast 2026
Feb 08, 2021 (The Expresswire) -- Global “Receptor Tyrosine Protein Kinase Targeted Drugs Market” (2021-2026) to its vast repository provides important...
The Express Wire · 02/09 01:52
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NERV. Analyze the recent business situations of Minerva through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NERV stock price target is 6.90 with a high estimate of 10.00 and a low estimate of 3.500.
EPS
Institutional Holdings
Institutions: 149
Institutional Holdings: 42.02M
% Owned: 98.46%
Shares Outstanding: 42.67M
TypeInstitutionsShares
Increased
30
2.26M
New
22
-1.44M
Decreased
20
1.16M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.96%
Pharmaceuticals & Medical Research
-1.89%
Key Executives
Chairman/Chief Executive Officer/Executive Director
Remy Luthringer
Chief Financial Officer/Executive Vice President
Geoffrey Race
Chief Operating Officer/Senior Vice President
Joseph Reilly
Senior Vice President/Chief Accounting Officer
Frederick Ahlholm
Senior Vice President/General Counsel
Devin Smith
Senior Vice President
Jay Saoud
Other
Michael Davidson
Lead Director/Independent Director
William Doyle
Independent Director
Hans Hasler
Independent Director
Jeryl Hilleman
Independent Director
G. van Heek
Independent Director
David Kupfer
Independent Director
Fouzia Laghrissi-Thode
Independent Director
Jan van Heek
No Data
  • All
  • Financials
  • Insiders
More
About NERV
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company's product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson's disease. MIN-101 is a compound that blocks serotonin receptors and sigma receptors, two receptors in the brain that are involved in the regulation of mood, cognition, sleep and anxiety. MIN-117 is meant to block a specific subtype of serotonin receptor called 5-hydroxytryptamine type 1A (5-HT1A). MIN-202 is a selective orexin 2 receptor antagonist. MIN-301 is a soluble recombinant form of the Neuregulin-1b1 (NRG-1b1) protein, for the treatment of Parkinson's disease.

Webull offers kinds of Minerva Neurosciences Inc stock information, including NASDAQ:NERV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NERV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NERV stock methods without spending real money on the virtual paper trading platform.